ZIIHERA and TEVIMBRA Combo Improves mOS by >7 Months in HER2+ GEA
BeOne Medicines’ Phase 3 HERIZON-GEA-01 trial showed ZIIHERA plus TEVIMBRA and chemotherapy achieved median overall survival of 26.4 months (HR 0.72; P = 0.0043), representing a 28% reduction in risk of death and over seven-month OS improvement versus control. The combination also delivered median progression-free survival of 12.4 months (HR 0.63; P < 0.0001), a 37% lower risk of disease progression regardless of PD-L1 status.
1. Unusual Options Activity Signals Investor Interest in ONC
Recent data from the options market reveal a surge in call option volume on BeOne Medicines Ltd. (Nasdaq: ONC). Over the past five trading sessions, call open interest has risen by 45%, with institutional desks initiating multi‐leg bullish spreads targeting strikes approximately 20% above current levels. Average daily implied volatility for near‐term contracts has climbed from 60% to 75%, suggesting traders are pricing in a significant move in ONC shares before the end of Q1. This spike in derivatives activity may reflect growing optimism ahead of several clinical readouts and potential regulatory filings for ZIIHERA® and TEVIMBRA® in key markets.
2. HERIZON‐GEA‐01 Interim OS Data Reinforce ONC’s Pipeline Strength
BeOne Medicines today presented first interim overall survival (OS) results from its Phase 3 HERIZON‐GEA‐01 trial evaluating ZIIHERA® (zanidatamab) plus chemotherapy, with and without PD-1 inhibitor TEVIMBRA®. In the triplet arm (n=302), median OS reached 26.4 months versus control, representing a 28% reduction in risk of death (HR=0.72, P=0.0043) and a more than seven-month gain in survival. The doublet arm (n=304) showed a median OS of 24.4 months with a strong trend toward statistical significance. Both experimental regimens also delivered median progression-free survival of 12.4 months, outperforming the control arm’s 8.1 months, and objective response rates above 69%, with durations of response extending beyond 14 months. These outcomes position ONC’s candidates for potential regulatory filings in the U.S., China and Asia Pacific later this year.
3. Regulatory and Commercial Milestones on the Horizon
Following the encouraging HERIZON-GEA-01 data, BeOne plans to submit supplemental Biologics License Applications to the U.S. FDA for TEVIMBRA® and to China’s NMPA for both TEVIMBRA® and ZIIHERA®. The company also intends to engage regulators in its Asia Pacific territories, where it holds commercial rights for ZIIHERA®. With a global Phase 3 population of 914 patients across more than 30 countries, ONC is on track to meet dual primary endpoints of progression-free survival and overall survival, setting the stage for label expansions into first-line HER2-positive metastatic gastroesophageal adenocarcinoma. Investors should monitor upcoming regulatory decisions, as approvals in the U.S. and China could significantly enhance ONC’s market potential and revenue forecasts.